J Cancer 2019; 10(9):2035-2046. doi:10.7150/jca.29421 This issue


Unravel the molecular mechanism of XBP1 in regulating the biology of cancer cells

Weimei Shi1*, Zhixi Chen1*, Linfu Li1*, Hai Liu1, Rui Zhang1, Qilai Cheng1, Daohua Xu2✉, Longhuo Wu1✉

1. College of Pharmacy, Gannan Medical University, Ganzhou China, 341000
2. Department of Pharmacology, Guangdong Medical University, Dongguan China, 523808
*These authors contributed equally to this study

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Shi W, Chen Z, Li L, Liu H, Zhang R, Cheng Q, Xu D, Wu L. Unravel the molecular mechanism of XBP1 in regulating the biology of cancer cells. J Cancer 2019; 10(9):2035-2046. doi:10.7150/jca.29421. Available from https://www.jcancer.org/v10p2035.htm

File import instruction


Cancer cells are usually exposed to stressful environments, such as hypoxia, nutrient deprivation, and other metabolic dysfunctional regulation, leading to continuous endoplasmic reticulum (ER) stress. As the most conserved branch among the three un-folded protein response (UPR) pathways, Inositol-requiring enzyme 1α (IRE1α)-X-box-binding protein 1 (XBP1) signaling has been implicated in cancer development and progression. Active XBP1 with transactivation domain functions as a transcription factor to regulate the expression of downstream target genes, including many oncogenic factors. The regulatory activity of XBP1 in cell proliferation, apoptosis, metastasis, and drug resistance promotes cell survival, leading to tumorigenesis and tumor progression. In addition, the XBP1 peptides-based vaccination and/or combination with immune-modulatory drug administration have been developed for effective management for several cancers. Potentially, XBP1 is the biomarker of cancer development and progression and the strategy for clinical cancer management.

Keywords: XBP1, cancer cells, UPR, tumorigenesis, metastasis, drug resistance